The current study examined the interaction between the cannabinoid CB1 receptor agonists Δ9-tetrahydrocannabinol and (R)-methanandamide in combination with the cannabinoid CB1 receptor antagonist SR-141716A (N-(piperidin-1-yl)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide HCl) in rats responding for food on a fixed ratio (FR-10) schedule of food reinforcement. The study provided only limited evidence for antagonism by SR-141716A (at 1 mg/kg but not with 0.3, 3 and 10 mg/kg) of the rate suppressant effects induced by the cannabinoid CB1 receptor agonist Δ9-tetrahydrocannabinol (and only at the single dose of 5.6 mg/kg Δ9-tetrahydrocannabinol). (R)-Methanandamide in combination with SR-141716A resulted in a greater rate suppression compared to that induced by (R)-methanandamide alone. Thus, SR-141716A augmented the rate-decreasing effects of (R)-methanandamide and only minimally altered the rate-decreasing effects of Δ9-tetrahydrocannabinol. Additionally, high doses (10 and 30 mg/kg) of SR-141716 singly consistently suppressed the rate of responding. The current results coupled with our previous data examining combinations of Δ9-tetrahydrocannabinol or (R)-methanandamide and SR-141716 (see text) underscore pharmacological/behavioral differences (whether quantitative or qualitative) between the cannabinoid CB1 agonists (R)-methanandamide and Δ9-tetrahydrocannabinol revealed by their interactions with the cannabinoid CB1 antagonist SR-141716.
- Behavior, schedule controlled
ASJC Scopus subject areas